TABLE 1

Uptake (%ID/g) of ¹¹¹In-RGD₂ Plus 50 μg of RGD₂ in Mice Treated with Bevacizumab

	Tumor type
	SK-RC-52		FaDu
Time after treatment (d)	Control	Bevacizumab	Control	Bevacizumab
≤3	0.98 ± 0.02	0.89 ± 0.06	0.24 ± 0.04	0.26 ± 0.07
10	0.48 ± 0.05	0.48 ± 0.07	0.13 ± 0.02	0.18 ± 0.06
21	0.36 ± 0.02	0.31 ± 0.03	0.20 ± 0.05	0.17 ± 0.01